Self-nano-emulsifying drug delivery systems: An update of the biopharmaceutical aspects

Expert Opinion on Drug Delivery

Volumn 12, Issue 7, 2015, Pages 1121-1133

  Cherniakov, Irina ^a   Domb, Abraham J ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Intra enterocyte metabolism; Lymphatic delivery; Oral bioavailability; P gp efflux; Poorly water soluble drugs; Self emulsifying drug delivery systems; Solubilization

Indexed keywords

EXCIPIENT; LIPID; DRUG; EMULSION; WATER;

CELL METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG PENETRATION; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; IN VIVO STUDY; INTESTINE CELL; LIPOPHILICITY; PARTICLE SIZE; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; SELF NANO EMULSIFYING DRUG DELIVERY SYSTEM; STIMULATION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; EMULSION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; EXCIPIENTS; HUMANS; LIPIDS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 84931824661     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.999038     Document Type: Review

References (100)

1. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26
2. Hauss DJ. Oral lipid-based formulations enhancing the bioavailability of poorly water-soluble drugs. Informa Healthcare USA, Inc; New-York: 2007
3. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-20
4. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96
5. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58(3): 173-82
6. Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008; 60(6): 673-91
7. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995; 12(11): 1561-72
8. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 1989; 6(1): 40-3
9. Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13(12): 1838-45
10. Bekerman T, Golenser J, Domb A. Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci 2004; 93(5): 1264-70
11. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm 2009; 35(12): 1479-86
12. Thomas K, Koelwel C, Machei U, et al. Three generations of cyclosporine a formulations: an in vitro comparison. Drug Dev Ind Pharm 2005; 31(4-5): 357-66
13. Larsen AT, Ohlsson AG, Polentarutti B, et al. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci 2013; 48(1-2): 339-50
14. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47(1): 3-19
15. Gershanik T, Haltner E, Lehr CM, et al. Charge-dependent interaction of selfemulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. Int J Pharm 2000; 211(1-2): 29-36
16. Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci 1990; 79(3): 202-6
17. Gershanik T, Benita S. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. Pharm Dev Technol 1996; 1(2): 147-57
18. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50(1): 179-88
19. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6(3): 231-48
20. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25(1): 103-28
21. Carey MC, Small DM, Bliss CM. Lipid digestion and absorption. Annu Rev Physiol 1983; 45: 651-77
22. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm 2011; 3(1): 4-8
23. Basalious EB, Shawky N, Badr-Eldin SM. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm 2010; 391(1-2): 203-11
24. Dietschy JM, Sallee VL, Wilson FA. Unstirred water layers and absorption across the intestinal mucosa. Gastroenterology 1971; 61(6): 932-4
25. Wilson FA, Sallee VL, Dietschy JM. Unstirred water layers in intestine: rate determinant of fatty acid absorption from micellar solutions. Science 1971; 174(13): 1031-3
26. Dimitrijevic D, Shaw AJ, Florence AT. Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol 2000; 52(2): 157-62
27. Quan YS, Hattori K, Lundborg E, et al. Effectiveness and toxicity screening of various absorption enhancers using Caco- 2 cell monolayers. Biol Pharm Bull 1998; 21(6): 615-20
28. Koga K, Ohyashiki T, Murakami M, et al. Modification of ceftibuten transport by the addition of non-ionic surfactants. Eur J Pharm Biopharm 2000; 49(1): 17-25
29. Dudeja PK, Anderson KM, Harris JS, et al. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995; 319(1): 309-15
30. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of Pglycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007; 4(3): 465-74
31. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84(21): 7735-8
32. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of Pglycoprotein encoded by a multidrugresistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48(7): 1926-9
33. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66(1): 62-8
34. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996; 13(4): 528-34
35. Chen ML. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Deliv Rev 2008; 60(6): 768-77
36. Katneni K, Charman SA, Porter CJ. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci 2007; 96(2): 280-93
37. Zhang H, Yao M, Morrison RA, et al. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 2003; 26(9): 768-72
38. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13(3): 129-34
39. Trausch B, Oertel R, Richter K, et al. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995; 16(5): 403-14
40. Elgart A, Cherniakov I, Aldouby Y, et al. Improved oral bioavailability of BCS class 2 compounds by self nanoemulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res 2013; 30(12): 3029-44
41. Benet LZ. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 2010; 106(3): 162-7
42. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9(3): 215-36
43. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008; 38(7-8): 778-801
44. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71(1): 11-20
45. Engel A, Oswald S, Siegmund W, et al. Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm 2012; 9(9): 2577-81
46. Peters WH, Kremers PG. Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol 1989; 38(9): 1535-8
47. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270(1): 414-23
48. de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253(1): 387-94
49. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90(5): 1871-8
50. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
51. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoidinducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80(4): 1029-36
52. Benet LZ, Wu CY, Hebert MF, et al. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release 1996; 39: 139-43
53. Komura H, Iwaki M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 2011; 43(4): 476-98
54. Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2008; 97(5): 1775-800
55. Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 2006; 58(9): 1183-91
56. Ren X, Mao X, Si L, et al. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm 2008; 70(1): 279-88
57. Ren X, Mao X, Cao L, et al. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci 2009; 36(4-5): 401-11
58. CM OD. Anatomy and physiology of the lymphatics. In: William N, Charman VJS, editors. Lymphatic transport of drugs. CRC Press, Inc; Boka Raton, FL: 1992
59. Cohen DE, Armstrong EJ. Biochemistry and physiology of cholesterol and lipoprotein metabolism. In: Golan DE, Tasjian AH, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology. 3rd edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2011
60. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 15(5): 405-15
61. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001; 50(1-2): 61-80
62. Holm R, Porter CJ, Müllertz A, et al. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res 2002; 19(9): 1354-61
63. Khoo SM, Shackleford DM, Porter CJ, et al. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res 2003; 20(9): 1460-5
64. Seeballuck F, Lawless E, Ashford MB, et al. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res 2004; 21(12): 2320-6
65. Lind ML, Jacobsen J, Holm R, et al. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80. Eur J Pharm Sci 2008; 35(3): 211-18
66. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29(3-4): 278-87
67. Boyd M, Risovic V, Jull P, et al. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J Pharmacol Toxicol Methods 2004; 49(2): 115-20
68. Khoo SM, Edwards GA, Porter CJ, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci 2001; 90(10): 1599-607
69. Edwards GA, Porter CJ, Caliph SM, et al. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 2001; 50(1-2): 45-60
70. Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. 2007; 32(1): 24-32
71. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005; 26(5): 394-404
72. Gershkovich P, Fanous J, Qadri B, et al. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J Pharm Pharmacol 2009; 61(1): 31-9
73. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly watersoluble LTB4 inhibitor. J Pharm Sci 1998; 87(2): 164-9
74. Wu H, Zhou A, Lu C, et al. Examination of lymphatic transport of puerarin in unconscious lymph ductcannulated rats after administration in microemulsion drug delivery systems. Eur J Pharm Sci 2011; 42(4): 348-53
75. Nielsen FS, Petersen KB, Mullertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm 2008; 69(2): 553-62
76. Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11(1): 151-5
77. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54(6): 925-75
78. Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc 1999; 31(6): 2203-5
79. Shimomura M, Masuda S, Saito H, et al. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res 2002; 103(2): 215-22
80. Elgart A, Cherniakov I, Aldouby Y, et al. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids 2012; 165(4): 438-53
81. Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 2005; 5(2): 79-83
82. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49(4): 373-8
83. Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990; 30(7): 643-53
84. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and firstpass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58(5): 492-7
85. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22(1): 11-23
86. Arida AI, Al-Tabakha MM, Hamoury HA. Improving the high variable bioavailability of griseofulvin by SEDDS. Chem Pharm Bull (Tokyo) 2007; 55(12): 1713-19
87. Ofokansi KC, Chukwu KI, Ugwuanyi SI. The use of liquid selfmicroemulsifying drug delivery systems based on peanut oil/tween 80 in the delivery of griseofulvin. Drug Dev Ind Pharm 2009; 35(2): 185-91
88. Taha E, Ghorab D, Zaghloul AA. Bioavailability assessment of vitamin A self-nanoemulsified drug delivery systems in rats: a comparative study. Med Princ Pract 2007; 16(5): 355-9
89. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11(2): 301-4
90. Borhade V, Nair H, Hegde D. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech 2008; 9(1): 13-21
91. Abdalla A, Klein S, Mader K. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets. Eur J Pharm Sci 2008; 35(5): 457-64
92. Cuine JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 2008; 97(2): 995-1012
93. Zhou L, Naraharisetti SB, Liu L, et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010; 31(4): 228-42
94. Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly watersoluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 2009; 98(10): 3582-95
95. Liu H, Shang K, Liu W, et al. Improved oral bioavailability of glyburide by a selfnanoemulsifying drug delivery system. J Microencapsul 2014; 31(3): 277-83
96. Singh G, Pai RS. Optimized selfnanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv 2014; 11(7): 1023-32
97. Chopra M, Nayak UY, Gurram AK, et al. Formulation, characterization and In vivo evaluation of selfnanoemulsifying drug delivery system for oral delivery of valsartan. Cur Nutr Food Sci 2014; 10(2): 263-70
98. Khan AW, Kotta S, Ansari SH, et al. Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly watersoluble grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo evaluation. Drug Deliv 2014. [Epub ahead of print
99. Ghai D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective b1-adrenoreceptor blocker talinolol. Nanomedicine 2012; 8(5): 618-26
100. Abdelbary G, Amin M, Salah S. Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation. Pharm Dev Technol 2013; 18(6): 1294-304